Related Experiment Video
Updated: May 30, 2026

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
Published on: December 26, 2014
Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls
Steven P Luckman1, Nils Erik Gilhus, Fredrik Romi
1Section for Neurology, Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.
Abstract:
MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical role in neuromuscular signaling by controlling acetylcholine receptor clustering. High MMP-3 levels in a proportion of myasthenia gravis (MG) patients have been reported. A pathogenic role of MMP-3 in other neurological disorders has been suggested but not proven. We have therefore examined the levels of MMP-3 in 124 MG patients and compared them to 59 multiple sclerosis (MS) patients, 74 epilepsy patients, 33 acute stroke patients, and 90 healthy controls. 15.3% of the patients in the MG group were MMP-3-positive (defined as higher than cutoff value 48 ng/mL) with very high mean MMP-3 concentration (79.9 ng/mL), whereas the proportion of MMP-3 positive patients in the MS (3.4%), epilepsy (6.7%), stroke (0%), and the control group (4.4%) was significantly lower. Mean MMP-3 concentration in the total MG group (25.5 ng/mL) was significantly higher than in the MS (16.6 ng/mL) and stroke (11.7 ng/mL) groups, but did not differ significantly from the epilepsy (19.4 ng/mL) and the control group (23.4 ng/mL). MMP-3 may have a specific pathogenic effect in MG in addition to being associated with autoimmune diseases in general.
Insights
Matrix metalloproteinase-3 (MMP-3) is elevated in myasthenia gravis (MG) patients, suggesting a specific role in this autoimmune neuromuscular disorder. MMP-3 levels were significantly higher in MG compared to multiple sclerosis and stroke patients.
Area of Science:
- Neurology
- Immunology
- Biochemistry
Background:
- Matrix metalloproteinase-3 (MMP-3) degrades proteins like agrin, crucial for neuromuscular signaling and acetylcholine receptor clustering.
- Elevated MMP-3 levels have been observed in some myasthenia gravis (MG) patients.
- A pathogenic role for MMP-3 in neurological disorders is suspected but not confirmed.
Purpose of the Study:
- To investigate and compare MMP-3 levels in myasthenia gravis (MG) patients versus other neurological conditions and healthy controls.
- To determine if MMP-3 has a specific association with MG pathogenesis.
Main Methods:
- Quantified MMP-3 levels in 124 MG patients, 59 multiple sclerosis (MS) patients, 74 epilepsy patients, 33 acute stroke patients, and 90 healthy controls.
- Defined MMP-3 positivity as concentrations above 48 ng/mL.
- Compared mean MMP-3 concentrations across all study groups.
Main Results:
- 15.3% of MG patients were MMP-3 positive with a mean concentration of 79.9 ng/mL.
- MMP-3 positivity was significantly lower in MS (3.4%), epilepsy (6.7%), stroke (0%), and control (4.4%) groups.
- Mean MMP-3 concentration in MG patients (25.5 ng/mL) was significantly higher than in MS (16.6 ng/mL) and stroke (11.7 ng/mL) groups.
Conclusions:
- MMP-3 may play a specific pathogenic role in myasthenia gravis.
- Elevated MMP-3 levels in MG suggest a potential link beyond general autoimmune disease association.
- Further research is warranted to elucidate MMP-3's precise function in MG.
Related Concept Videos
Myasthenia Gravis ll: Pathophysiology
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
